Guido Lanza has over 25 years of experience building technology companies and complex artificial intelligence (AI) platforms. As the Vice President of Integrated Research at Valo Health, Guido leads the buildout and execution of the company's next-generation AI-driven molecule design capabilities –– which are the centerpiece of a multi-year strategic partnership between Valo and Charles River Labs (CRL) called Logica. Logica is an AI-powered drug solution that seamlessly translates CRL clients' biological targets into optimized preclinical candidate nominations. Guido joined Valo as part of the company's acquisition of Numerate, a successful biotech Guido co-founded and served as CEO with the mission to change the drug discovery paradigm using AI to unlock otherwise inaccessible emerging biology. Guido led Numerate’s efforts to secure multiple rounds of funding, as well as secured several high-profile collaborations with large pharmaceutical companies, academic collaborations, and built a pipeline of first-in-class therapeutic programs.